Biolinq Names Diabetes Industry Expert Richard Yang Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- Biolinq, a medical device company that has developed a novel wearable biosensor platform to measure continuous glucose for the management of diabetes and other clinical conditions, has named Richard Yang as its new Chief Executive Officer.

Yang brings to Biolinq more than 20 years of global experience in med-tech innovation, product development and commercial strategy, with expertise in continuous glucose monitoring (CGM) technologies and digital health solutions. Yang’s leadership experience includes two decades at top tier medical device companies including Medtronic and Dexcom.

Yang’s career in medical devices began with MiniMed insulin pumps and glucose sensing when he was a member of the original team that launched the CGM category and quickly established his early commercial experience at Medtronic Diabetes. More recently, Yang spent nearly a decade at Dexcom in an executive leadership role with the team that contributed to its long-term success.

“We’ve had the pleasure of getting to know Rich well over the past several years and we’re thrilled to welcome him on board to lead Biolinq to the next stage of our development,” said Jared Tangney, PhD, Biolinq’s co-founder. Tangney, who previously served as CEO, will assume the role of President & COO. “Throughout his career, Rich has repeatedly helped lead companies with groundbreaking technology to category-defining status.”

“Biolinq was a natural draw for me, particularly due to its innovative approach to dermal sensing and profound microneedle array technology that has the potential to significantly transform the user experience,” said Yang. “It’s an honor to help build upon the vision of the company’s founders and I look forward to advancing new technologies that will serve the diabetes community and beyond.”

Biolinq is a medical device company developing a wearable biosensor platform that measures biomarkers important to the management of many clinical conditions including diabetes. The company's first product is a needle-free, intelligent continuous glucose monitoring system. Learn more at www.Biolinq.me.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005928/en/

Paul Williams, 310-569-0023, [email protected]

Source: Biolinq

You May Also Be Interested In

• TNS is the Only Provider in Europe to Offer Full-Service, Vendor-Neutral Market Data Management Solutions for Financial Institutions
• Sterling to Add Fixed Income Support to Risk & Margin Service
• Hemogenyx Pharmaceuticals PLC Announces Final Results